DETAILED ACTION
Notice of Pre-AIA or AIA Status
The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA .
In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status.
Current Status of 18/737,044
This Office Action is responsive to the amended claims of 21 January 2025.
Claims 1-3, 5-6, 24, 27-28, 30, 32, 35, and 37-46 have been examined on the merits. Claims 1-3, 28, 30, 32, and 35 are currently amended. Claims 5-6, 24, 27, and 37-46 are original.
Priority
The effective filing date is 13 November 2019.
Information Disclosure Statement
The information disclosure statements (IDS) submitted on 19 March 2026; 27 June 2025; and 27 January 2025, are in compliance with the provisions of 37 CFR 1.97. Accordingly, the information disclosure statements are being considered by the examiner.
Claim Rejections - 35 USC § 112
The following is a quotation of 35 U.S.C. 112(b):
(b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention.
The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph:
The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.
Claims 37, 39-42, and 44 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention.
Claim 37 is drawn to a method of administering a crystalline compound of claim 1. The act of administering a compound (implying “one compound”) renders the metes and bounds of the claim undefined (hence rendering claim 37 indefinite under 35 USC 112(b)). The artisan does not know how it is possible to administer just one compound (crystalline form thereof or otherwise) to a patient. However, it is possible to administer a pharmaceutical composition comprising a (crystalline form A of the) compound (claim 38).
Claims 39-42 are similarly rejected as indefinite under 35 USC 112(b) since these claims refer back to claim 37 but do not remedy the rationale underpinning the basis for rejecting claim 37.
Please cancel claims 37 and 39-42 to render moot the rejection.
Claim 40 contains at least one occurrence of a limitation within parentheticals (see, for example: “arthritis (rheumatoid and psoriatic)”) which renders the metes and bounds of the claim undefined (hence rendering claim 40 indefinite under 35 USC 112(b)). Claim 40 is indefinite because limitations cannot be surrounded by parentheticals. Limitations surrounded by parentheticals give rise to confusion: are the limitations within the parentheticals merely exemplary or are they required by the claim?
Claim 44 is rejected as indefinite under 35 USC 112(b) for the same rationale.
Please strike the parentheticals surrounding the limitations within the claims to render moot this rejection.
The following is a quotation of 35 U.S.C. 112(d):
(d) REFERENCE IN DEPENDENT FORMS.—Subject to subsection (e), a claim in dependent form shall contain a reference to a claim previously set forth and then specify a further limitation of the subject matter claimed. A claim in dependent form shall be construed to incorporate by reference all the limitations of the claim to which it refers.
The following is a quotation of pre-AIA 35 U.S.C. 112, fourth paragraph:
Subject to the following paragraph [i.e., the fifth paragraph of pre-AIA 35 U.S.C. 112], a claim in dependent form shall contain a reference to a claim previously set forth and then specify a further limitation of the subject matter claimed. A claim in dependent form shall be construed to incorporate by reference all the limitations of the claim to which it refers.
Claims 2-3 and 5-6 are rejected under 35 U.S.C. 112(d) or pre-AIA 35 U.S.C. 112, 4th paragraph, as being of improper dependent form for failing to further limit the subject matter of the claim upon which it depends, or for failing to include all the limitations of the claim upon which it depends.
Dependent claims 2-3 and 5-6 attempt to further define the polymorph of instant claim 1 by physico-chemical data (such as XRPD and melting point data). Independent claim 1 recites “crystalline Form A” which inherently contains all the limitations/physico-chemical data of claims 2-3 and 5-6. If claim 1 did not contain the inherent limitations of claims 2-3 and 5-6, it would not technically be “crystalline Form A”. Thus, claims 2-3 and 5-6 are rejected under 35 USC 112(d) since these claims 2-3 and 5-6 do not further limit what is already (inherently) disclosed within claim 1.
Applicant may cancel the claim(s), amend the claim(s) to place the claim(s) in proper dependent form, rewrite the claim(s) in independent form, or present a sufficient showing that the dependent claim(s) complies with the statutory requirements.
Double Patenting
The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).
A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on nonstatutory double patenting provided the reference application or patent either is shown to be commonly owned with the examined application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. See MPEP § 717.02 for applications subject to examination under the first inventor to file provisions of the AIA as explained in MPEP § 2159. See MPEP § 2146 et seq. for applications not subject to examination under the first inventor to file provisions of the AIA . A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b).
The filing of a terminal disclaimer by itself is not a complete reply to a nonstatutory double patenting (NSDP) rejection. A complete reply requires that the terminal disclaimer be accompanied by a reply requesting reconsideration of the prior Office action. Even where the NSDP rejection is provisional the reply must be complete. See MPEP § 804, subsection I.B.1. For a reply to a non-final Office action, see 37 CFR 1.111(a). For a reply to final Office action, see 37 CFR 1.113(c). A request for reconsideration while not provided for in 37 CFR 1.113(c) may be filed after final for consideration. See MPEP §§ 706.07(e) and 714.13.
The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/patent/patents-forms. The actual filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA /25, or PTO/AIA /26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to www.uspto.gov/patents/apply/applying-online/eterminal-disclaimer.
Claims 1-3, 5-6, 24, 27-28, 30, 32, 35, and 37-46 are rejected on the ground of anticipatory nonstatutory double patenting as being unpatentable over claims 1-46 of U.S. Patent No. 12,006,318 B2. The instant amended claims of 21 January 2025 were used to write this rejection.
Although the claims at issue are not identical, they are not patentably distinct from each other because the reference claims anticipate the instant claims. For example, reference claims 1-4, drawn to compound 2-((R)-3-(1-(1-((R)-1-(2,4-Dichlorophenyl)ethyl)-3-(trifluoromethyl )-1H-pyrazolo[3,4-b ]pyrazin-6-yl)azetidin-3-yl)piperidin-1-yl)ethan-1-ol benzene sulfonate in crystalline form, further defined by XRPD peaks, anticipates instant claims 1-3, drawn to the same crystalline Form A.
Reference claims 5-6 anticipate instant claims 5-6, drawn to same Figure 1 XRPD and melting point data.
Reference claim 24, drawn to a pharmaceutical composition comprising said crystalline Form A, anticipates instant claim 24, drawn to same.
Reference claim 27, drawn to “oral tablet dosage form” anticipates instant claim 27, drawn to same.
Reference claims 28-29, drawn to 75 mg and 25 mg of the crystalline Form A, anticipates instant claim 28, drawn to same.
Reference claims 30-31, drawn to “sodium lauryl sulfate” wetting agent, anticipates instant claim 30, drawn to same.
Reference claims 32-34, drawn to “lactose monohydrate” and “50% by weight” anticipate instant claim 32, drawn to same.
Reference claims 35-36, drawn to disintegrant “cros-carmellose sodium” anticipates instant claim 35, drawn to same.
Reference claim 37, drawn to a method of treating an immune, inflammatory, or cancer-related disease or disorder by administering the crystalline Form A, anticipates instant claim 37, drawn to same.
Reference claim 38, drawn to a method of treating an immune, inflammatory, or cancer-related disease or disorder by administering a pharmaceutical composition comprising the crystalline Form A, anticipates instant claim 38, drawn to same.
The diseases of reference claims 39-40 anticipate the same of instant claims 39-40.
Reference claims 41-42, drawn to co-administration with pembrolizumab as the “another therapeutic agent” anticipates instant claims 41-42, drawn to same.
The diseases of reference claims 43-44 anticipate the same of instant claims 43-44.
Reference claims 45-46, drawn to co-administration with pembrolizumab as the “another therapeutic agent” anticipates instant claims 45-46, drawn to same.
Conclusion
No claims are presently allowable as written.
Claim 1 is free of the prior art.
There is no known prior art reference that either teaches or anticipates a crystalline Form A of the compound 2-((R)-3-(1-(1-((R)-1-(2,4-Dichlorophenyl)ethyl)-3-(trifluoromethyl )-1H-pyrazolo[3,4-b ]pyrazin-6-yl)azetidin-3-yl)piperidin-1-yl)ethan-1-ol benzene sulfonate:
PNG
media_image1.png
392
535
media_image1.png
Greyscale
(see illustration within Specification paragraph [0171]) of instant base claim 1.
The reference BECK (WO 2018/022992 A1, referenced in IDS of 01/27/2025), discloses the compound:
PNG
media_image2.png
217
222
media_image2.png
Greyscale
(see page 146), which is structurally similar to the underlying compound of base instant claim 1 and paragraph [0171] of the Specification.
However, BECK is a close art, and not a prior art reference since this compound is one of many species of the invention of BECK (thus a picking and choosing problem: why hone-in on just this compound to attempt to use BECK as prior art?). Furthermore, BECK does not teach or anticipate (1) a crystalline form of (2) “benzenesulfonate”, which are two differences too many with the instant claims to permit BECK to be used in an obviousness rejection.
Moreover, while it may be obvious to combine a pharmaceutically acceptable salt with an active ingredient like the 2-((R)-3-(1-(1-((R)-1-(2,4-Dichlorophenyl)ethyl)-3-(trifluoromethyl )-1H-pyrazolo[3,4-b ]pyrazin-6-yl)azetidin-3-yl)piperidin-1-yl)ethan-1-ol of instant claim 1, above, it is not obvious to make a particular crystalline form of a particular salt (benzene sulfonate) of said active ingredient, especially when the instant claim 1 is further limited by very specific XRPD peaks.
Moreover, Applicants discovered unexpected/surprising results in terms of superior stability, bioavailability, low hygroscopicity, and high solubility during prolonged storage, thereby making the crystalline polymorph of benzene sulfonate salt of the compound, above, ideal for pharmaceutical development (see paragraph [0168] of Specification).
Furthermore, there is no known rationale (and no known prior art reference providing said rationale) that would permit modifying the teachings of BECK to arrive at the instant invention.
Any inquiry concerning this communication or earlier communications from the examiner should be directed to JOHN S KENYON whose telephone number is (571)270-1567. The examiner can normally be reached Monday-Friday 10a-6p.
Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice.
If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Andrew D Kosar can be reached at (571) 272-0913. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.
Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.
/JOHN S KENYON/Primary Patent Examiner, Art Unit 1625